Nasopharyngeal (nay-zoh-fuh-RIN-jee-ul) carcinoma ciwon daji ne da ke faruwa a cikin nasopharynx, wanda ke bayan hanci da kuma saman bayan makogwaro.
Nasopharyngeal carcinoma ba kasafai ba ne a Amurka.Yana faruwa akai-akai a wasu sassan duniya - musamman kudu maso gabashin Asiya.
Nasopharyngeal carcinoma yana da wuyar ganowa da wuri.Wannan yana yiwuwa saboda nasopharynx ba shi da sauƙi a bincika kuma alamun ciwon daji na nasopharyngeal yana kama da wasu, yanayi na yau da kullum.
Ciwon daji na Nasopharyngeal yana faruwa ne a cikin matsakaita da tsofaffi masu shekaru sama da 40, kuma yana da fayyace halaye na yanki da na dangi, kuma adadin da ya faru a Guangdong ya kasance na farko a kasar Sin, wanda kuma aka fi sani da "Cancer Guangdong".
1.Jagoran Bincike da Maganin Ciwon Nasopharyngeal Carcinoma
A cikin Jagororin 2021 don Ganewa da Jiyya na Ciwon Nasopharyngeal Carcinoma, Ƙungiyar Magungunan Oncology ta kasar Sin (CSCO) ta haɗa da hanyoyin gano serological a cikin shaida na Class I don ganewar ciwon daji na nasopharyngeal, kuma ya nuna cewa haɗin EB-VCA-IgA da EB-NA1-IgA EB-virus antibodies iya ƙara farkon ganewar asali kudi na nasopharyngeal carcinoma da sau 3 (21% ~ 79%) da kuma rage hadarin mutuwa da 88%!Ƙwararrun Ƙwararrun Ƙwararru na 2019 akan Aikace-aikacen Clinical na Alamomi don Nasopharyngeal Carcinoma kuma ya nuna cewa EBV-EA-IgA alama ce ta kamuwa da cutar EBV na baya-bayan nan ko kuma yaduwa mai aiki na EBV, tare da babban matsayi na musamman, kuma ana amfani dashi sau da yawa don maganin ciwon daji na nasopharyngeal. da farkon ganewar asali.
Binciken ya nuna cewa gano abubuwan gano guda uku na EBV-VCA-IGA, EBV-EA-IGA da EB-NA1-IgA sun cika cikakkiyar nau'in nau'in nau'in EBV, wanda ke inganta haɓakar hankali da ƙayyadaddun gano cutar sankara na nasopharyngeal, yana rage ganowar da aka rasa, yana tabbatar da daidaito na tsinkayar cututtuka, da kuma annabta faruwar cutar shekaru 5-10 a gaba, wanda ya dace da babban gwajin ciwon daji na nasopharyngeal.
2.VCA-IgA+EA-IgA+NA1-IgA da Beijing Beier ta samar zai iya ba da ka'idar ganewar asali na farko don ciwon daji na Nasopharyngeal.
Magnetism particulate immuno chemistry luminescence Hanyar
| Sunan samfur | Gajarta |
| EB virus VCA-IgA kayan ganowa na rigakafi | EB-VCA-IgA |
| EB virus EA-IgA kayan ganowa na rigakafi | EB-EA-IgA |
| EB virus NA1-IgA kayan ganowa na rigakafi | EB-NA1-IgA |
Hanyar Elisa:
| Sunan samfur | Gajarta |
| EB virus VCA-IgA Elisa kit | EB-VCA-IgA |
| EB virus EA-IgA Elisa kit | EB-EA-IgA |
| EB virus NA1-IgA Elisa kit | EB-NA1-IgA |
3.Product Performance
Kayan gwajin VCA-IgA da Beijing Beier ta samar zai iya maye gurbin daidaitattun kayan aikin EU don ganowa da wuri da kuma tantance ciwon daji na hanci.
Jaridar Likitan Burtaniya (BMJ) (tasirin factor 16.378) ɗaya ne daga cikin manyan mujallun likitanci guda huɗu na duniya.A cikin 2017, ƙungiyar bincike ta buga takarda a cikin Jaridar Likita ta Burtaniya (BMJ) "Kimanin na'urorin VCA-IgA ELISA guda bakwai don gano cutar sankara na nasopharyngeal a China: gwajin kula da shari'a".
A cikin wannan takarda, an yi nazari da gwada marasa lafiya 200 tare da ciwon daji na nasopharyngeal (NPC) da 200 na al'ada na mutum (SYSUCC) daga Cibiyar Ciwon daji ta Jami'ar Sun Yat-sen, da kuma aikin EB-VCA-IgA (ELISA) kayan aikin da 8 ya samar. An kwatanta masu kera alamar a cikin kasuwar gida don kimanta aikin.Ƙarshen ita ce, kayan EBV-VCA-IgA (ELISA) da Beijing Beier ta samar yana da sakamako iri ɗaya kamar yadda EBV-VCA-IgA (ELISA) ta samar da reagent Oumeng, da EBV-VCA-IgA (ELISA). kit da Beijing Beier ta samar zai iya maye gurbin kayan da aka shigo da shi don gano wuri da kuma tantance cutar sankarau na hanci.An nuna bayanan masana'antun samfuran da ke shiga cikin gwajin a cikin Tebu 1, an nuna sakamakon gwajin a cikin Tebu 2, kuma an nuna ƙarshen gwajin a cikin Table 3.
Ƙarshen Gwaji
VCA-IgA kits guda uku-BB,HA da KSB- suna da tasirin bincike daidai da na daidaitattun kit. Ana iya maye gurbin su da daidaitaccen kit kuma ana iya amfani da haɗin gwiwar su a farkon ganowa da kuma tantancewa don NPC.
Lokacin aikawa: Fabrairu-23-2023